Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation

MT NewswiresJan 7 23:56

Express News | Immix Biopharma Inc: On Track for Next Program Update in Q1 2025

BreakingsJan 7 22:35

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

GlobeNewswireJan 7 22:34

Independent Director of Immix Biopharma Picks Up 5.6% More Stock

Simply Wall StDec 29, 2024 20:26

Sector Update: Health Care Stocks Decline Late Afternoon

MT NewswiresDec 20, 2024 04:56

Immix Biopharma Announces Initial Data From First Four Patients In NEXICART-2 US Study; Says All Four Patients Treated With NXC-201 Normalized Disease Markers Within 30 Days Of Dosing, Of Which, Two Are Already Classified As Complete

BenzingaDec 19, 2024 22:36